Skip to main content

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Completed · Phase 2 · NCT05423717

Conditions: Insomnia

At a glance

Research payments reported, 2025
$811,479
U.S. investigators named
9
Sites paid
10
Planned or actual enrollment
166

About the trial

Sponsor
Idorsia Pharmaceuticals Ltd.
Tested
Daridorexant 10 mg (drug), Daridorexant 25 mg (drug), Daridorexant 50 mg (drug), Placebo (drug)
Dates
Started 2022-09-06; completion 2026-02-05
Results posted
Not yet

This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to \< 18 years with insomnia disorder.

From ClinicalTrials.gov, last updated 2026-03-06. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Idorsia Pharmaceuticals US Inc reported $811,479 in research payments for this study in 2025 (124 payments).

Products named: Quviviq

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Encore Medical Research of Weston LLC $288,826
  • Clinitiative $229,830
  • Teradan Clinical Trials, LLC $87,166
  • Central Florida Pediatric Sleep Disorders Institute $64,173
  • Advarra, Inc. $35,220
  • University of South Florida $30,267
  • Preferred Research PArtners Nwa $21,741
  • Preferred Research PArtners, Inc. $20,441
  • Bogansleep Consultants, LLC $19,385
  • The University of Arizona $14,430

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.